Gilead CEO: Oral Version Of Covid Drug Remdesivir In Early Testing
Following are excerpts from CNBC interviews with Gilead Sciences, Inc. (NASDAQ:GILD) Chairman & CEO Daniel O’Day and Novavax, Inc. (NASDAQ:NVAX) President & CEO Stanley Erck on CNBC’s “Squawk on the Street” (M-F 9AM – 11AM ET) today, Monday, January 10. Following is a link to video on CNBC.com: Q4 2021 hedge fund letters, conferences and more Gilead CEO: Oral Version Of Covid Drug Remdesivir In Early TestingExcerpts from Gilead Sciences Chairman & CEO Daniel O’Day interview: O'Day On Impact Of RemdesivirDANIEL O’DAY: Remdesivir has really been, has had a major impact upon this pandemic over th...